RECURrence of Atrial Fibrillation After Cardioversion of Patients Randomized to Dapagliflozin or Usual Care

RECURrence of Atrial Fibrillation After Cardioversion of Patients Randomized to Open-label Treatment With Dapagliflozin or Usual Care

The goal of this clinical trial is to learn if drug dapagliflozin, a sodium-glucose transport-2 inhibitor, works to treat atrial fibrillation in adults. The main question it aims to answer is:

• Does the drug dapagliflozin reduce the recurrence rate of atrial fibrillation?

Researchers will compare drug dapagliflozin to standard therapy to see if drug dapagliflozin reduce the recurrence of atrial fibrillation.

Persons with atrial fibrillation who are planned for an electric cardioversion will:

• Take the drug dapagliflozin, or no drug, once a day for a maximum of 56 days
• Undergo a planned electric cardioversion of the atrial fibrillation
• Record the rhythm with a hand-held device that transmits the signal to researchers during the study period, but no longer than for 56 days

Inclusion Criteria:

• Patients with AF on ECG who are planned for electrical cardioversion within 7-26 days from inclusion-date.
• Age ≥ 55 years.
• Provided written informed consent.

Exclusion Criteria:

• Current treatment with an SGLT2 inhibitor.
• Prior/current diagnosis of heart failure.
• Type 1 diabetes mellitus.
• Estimated glomerular filtration rate (eGFR) < 25 mL/min/1.73m2.
• Pulmonary vein isolation within preceding 3 months or planned pulmonary vein isolation during the study period (56 days).
• Contraindications to SGLT2 inhibitors.
• Any condition or circumstance in which the patient should not participate in the study according to the study investigator.